Company profile: Sesen Bio
1.1 - Company Overview
Company description
- Provider of protein-based therapeutics focused on improving human health, including Vicineum, a locally administered targeted fusion protein for BCG-unresponsive non-muscle invasive bladder cancer, and VB6-845d, an anti-PSMA humabody-deBouganin fusion protein designed for tumor cell killing and overcoming drug resistance.
Products and services
- Innovative protein-based therapeutics development: Develops protein-based therapeutics, including targeted fusion and anti-PSMA humabody-deBouganin constructs to improve human health and treat diseases
- VB6-845d: Builds an anti-PSMA humabody-deBouganin fusion protein designed for tumor cell killing and overcoming drug resistance
- Vicineum: Engineers a locally administered targeted fusion protein for treating BCG-unresponsive non-muscle invasive bladder cancer specifically
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sesen Bio
Tempest Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics that modulate anti-tumor pathways, including TPST-1120, an oral PPARα antagonist designed to inhibit fatty acid oxidation and inflammation with potential in hepatocellular, renal cell, and cholangiocarcinoma, and TPST-1495, an oral dual EP2/EP4 antagonist in Phase 1/1b combination studies to reduce tumor growth and immune suppression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tempest Therapeutics company profile →
Volition
HQ: United States
Website
- Description: Provider of blood-based cancer diagnostics leveraging Nucleosomics to identify and measure nucleosomes and epigenetic changes for early detection and monitoring. Offerings include Nu.Q® Cancer assays, Nu.Q® NETs for detecting NETosis associated with diseases like sepsis, Nu.Q® Vet Cancer Test for dogs, Nu.Q® Discover for drug developers and scientists, and Capture-PCR™ liquid biopsy isolating tumor-derived ctDNA fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Volition company profile →
AroCell
HQ: Sweden
Website
- Description: Provider of biomarker-based diagnostic tests for cancer prognosis, monitoring, and follow-up, including the TK 210 ELISA measuring TK1 as a marker of increased cell turnover. Offers Oncology Diagnostics tools to capture critical clinical data for cancer patient management, and TUBEX TF, a rapid, sensitive in vitro test for detecting acute typhoid fever caused by Salmonella enterica.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AroCell company profile →
Secretome Therapeutics
HQ: United States
Website
- Description: Provider of neonatal mesenchymal stem cell-based therapeutics and secretome-based regenerative therapies for heart failure and neurodegenerative and dermatological diseases, including STM-01 for adult and pediatric heart failure and NEO2001 for chronic ischemic heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Secretome Therapeutics company profile →
IconOVir Bio
HQ: United States
Website
- Description: Provider of preclinical oncolytic virus therapies for cancer, developing ICVB-1042, an oncolytic adenovirus for advanced solid tumors featuring tumor-selective replication, broad tropism, and enhanced tumor cell killing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IconOVir Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sesen Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sesen Bio
2.2 - Growth funds investing in similar companies to Sesen Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sesen Bio
4.2 - Public trading comparable groups for Sesen Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →